China
Africa
Explore chapters and articles related to this topic
Radiolabeled Agents for Molecular Imaging and/or Therapy
Published in George C. Kagadis, Nancy L. Ford, Dimitrios N. Karnabatidis, George K. Loudos, Handbook of Small Animal Imaging, 2018
Dimitrios Psimadas, Eirini A. Fragogeorgi
The α-melanocyte-stimulating hormones (α-MSH) are produced in the pituitary gland and regulate skin pigmentation (Miao and Quinn 2007). The G-coupled receptors for α-MSH have been found in 80% of metastases from melanomas. Many α-MSH analogs have been developed for melanoma imaging, but unfortunately their in vivo tumor targeting properties are not satisfactory. New modified derivatives are currently under development and evaluation in melanoma-bearing mice, including 18F-, 64Cu-, and 177Lu-labeled α-MSH analogs (Yang et al. 2009; Gao et al. 2011; Lim et al. 2012).
Antioxidant and anti-tyrosinase activities of quercetin-loaded olive oil nanoemulsion as potential formulation for skin hyperpigmentation
Published in Journal of Dispersion Science and Technology, 2022
Cristiane C. Silva, Rogério B. Benati, Taís N. C. Massaro, Karina C. Pereira, Lorena R. Gaspar, Priscyla D. Marcato
Since melasma and other hyperpigmentation disorders are frequent in regions of the body that are exposed to the sun, ultraviolet radiation (UV) is considered a key factor for their development. The radiation on the skin stimulates the production of melanocyte-stimulating hormone (α-MSH), which in turn induces the modification of the melanocortin receptor (MC1R), leading to an increase in the transcription factor associated with melanogenesis (MITF). This factor activates tyrosinase and tyrosinase-related proteins (TRP) in the Golgi complex, leading to greater production of the pigments eumelanin and pheomelanin.[12,13] Reactive oxygen species (ROS) are also important mediators for the activation of the pathway. Therefore, there is a relationship between oxidative stress and hyperpigmentation disorders.[13,14]